Abbott to Acquire Exact Sciences
Exact Sciences is being acquired by Abbott, a global healthcare leader, at a total equity value of approximately $21 billion, the company announced today. “Together with Abbott, we can reach…
Tag Archives: Exact Sciences
Exact Sciences Announces Results from ALTUS Study
Exact Sciences announced today the results from its ALTUS Study, which is the largest prospective trial of a blood test for liver cancer surveillance in the United States, with more…
Exact Sciences Launches Cancerguard
Exact Sciences announced recently the launch of Cancerguard, a multi-cancer early detection (MCED) blood test that is now available as a laboratory-developed test (LDT) in the United States. According to…
Exact Sciences, Freenome Enter Agreement
Exact Sciences has entered into an exclusive agreement with Freenome, a biotechnology company pioneering an early cancer detection platform, the company announced recently. According to a release, Exact Sciences will…
Exact Sciences Earns Medicare Coverage for Oncodetect Test
Exact Sciences‘ Oncodetect molecular residual disease (MRD) test has received Medicare coverage through the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostic Services Program (MolDX), the company announced recently….
Exact Sciences Launches Oncodetect Test
Exact Sciences has launched Oncodetect, a new test designed to detect molecular residual disease (MRD) across multiple solid tumors, the company announced today. “Exact Sciences is transforming cancer care by…
Exact Sciences Launches Cologuard Plus Test
Exact Sciences has launched Cologuard Plus, a next-generation, noninvasive colorectal cancer screening text, the company announced today. According to a release, the Cologuard Plus test detects 95% of colorectal cancers…
Exact Sciences, Flatiron Health to Partner
Exact Sciences and Flatiron Health, a healthtech company dedicated to improving cancer care and advancing research, are partnering to accelerate clinical evidence generation for Exact Sciences’ molecular residual disease test…
Exact Sciences Presents New Data on MCED Test
Exact Sciences will be sharing results for its multi-cancer early detection (MCED) test at the American Association for Cancer Research (AACR) Special Conference taking place Nov. 13-16 in San Diego,…
Exact Sciences Earns FDA Approval for Cologuard Plus
Exact Sciences announced today that the U.S. Food and Drug Administration (FDA) approved its next-generation multitarget stool DNA test called Cologuard Plus. “Cologuard Plus sets a new performance standard in…
